skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Based on your last comments on June 24th about Sanofi could you please help me understand what's behind the recent drop with the stock recently and is this a good time to buy. Is it now at a "bargain" price what are the financial ratios you like and don't like about this stock? How do you feel about their pipeline of drugs?

Your last comment was SNY: Sanofi is a bit different than the others, being a $130 billion pharma company. The valuation fundamentals look fine, growth expectations are mid-to-low single digits on the top line and it pays a decent dividend. For an 'anchor' type of position, we would not take much issue with a name like this.

Read Answer Asked by James on August 11, 2022
Q: Would like to invest in the health sector, looking for growth over 1-2 years. Could you comment on the above stocks
Read Answer Asked by Howie on June 24, 2021
Q: Hello!
1) I would like to get a good, general US healthcare etf .. what might you recommend now? (Long term income investor)

2) also, I would like an etf that has companies like Sanofi and GSK, at decent weights .. what do you think? I see that VYMI has them but at very low percentages.

Appreciate your advice. Thank you!
Read Answer Asked by Patrik on April 21, 2020
Q: Hi folks,
In view of the coronavirus concerns, which are the companies you would recommend now as likely to grow strongly in the search for a vaccine or in the production of the equipment needed for fighting the spread of this virus ? Could you as well indicate the degree of risk involved in such companies and an order of priorities for the most interesting now ? As a start, what about GILD, INO, MRNA, REGN, SNY ?

Please deduct as many credits as you see fit.

And make sure you stay healthy…...we need you more than ever !

J. IDS
Read Answer Asked by Jacques on March 05, 2020
Q: SNY (not in your database) recently reported a poor quarter and so-so guidance. On the other hand, the P/E is now less than 12x, the dividend is substantial, and the pipeline should be broad enough to protect against single-drug risk. My sense is that it's long-term-investable, but less attractive than other beaten-down pharma blue-chips (say, LLY); your opinion?
Read Answer Asked by John on February 16, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!